Open Nav

Please submit your session questions in advance at

IMV Inc.

  • Frederic Ors, IMV Inc.

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at

  • Date:Monday, February 11
  • Time:2:45 PM - 3:00 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23277
  • Goal for Presentation:Raise awareness on technology/product and clinical
  • Company Website:
  • Company HQ City:Dartmouth
  • Company HQ State:Nova Scotia
  • Company HQ Country:Canada
  • Market Cap:250M
  • Ticker:IMV
  • Exchange:TSX, NASDAQ
  • CEO/Top Company Official:Frederic Ors
  • Year Founded:2000
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:DPX- Survivac
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
Frederic Ors
IMV Inc.